Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effectiveness and toxicity of maintenance bioimmunotherapy available for epithelial ovarian cancer and to evaluate the impact on the quality of life (QoL) of maintenance bioimmunotherapy. We will update this review once new treatments are available, but the first step is to evaluate interferon‐alpha, matrix metalloprotease inhibitor, monoclonal antibodies, and some radioimmunotherapies, which have been studied by phase trials.